ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

TTRX vs AVIR // OPTIONS IMPLIED MOVE & PUT/CALL SKEW

Turn Therapeutics Inc. (NASDAQ) VS. Atea Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: TTRX 2 — AVIR 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TTRX VS. AVIR) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC TTRX AVIR SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -28.30% -35.00% +6.70 TTRX /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -0.78% — — TIE /fcf-yield <GO>
Operating Margin — — — TIE /operating-margins <GO>
Net Profit Margin — — — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 1/9 3/9 -2.00 AVIR /piotroski-score <GO>
Options Implied Move & Put/Call Skew ACTIVE — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 43.8 36.0 +7.80 TTRX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $318.5M $329.6M -$11.2M AVIR /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR TTRX REV AVIR REV TTRX GROSS % AVIR GROSS % TTRX FCF AVIR FCF
FY 2025 $16.4M $506.5M — — -$2.6M -$132.0M
FY 2024 $5.0M $540.3M — — -$1.4M -$135.5M
FY 2023 — $459.7M — — — -$85.4M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TTRX // BETA —
AVIR // BETA —